|
MANUSCRIPT SUBMISSION REQUIREMENTS
Authors must submit all new manuscripts directly to Daniel G. Haller, MD, Editor-in-Chief, using the online Manuscript Processing System.
Biomarker Submissions (REMARK Guidelines)
Submissions need to be REMARK compliant as established in NCI-EORTC's "Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)" (J Natl Cancer Inst 97:1180, 2005). Authors of biomarker manuscripts should report biomarkers that have a clear biologic relevance to a particular tumor type. Studies that are clinically important, provide significant validation, and have a strong underlying hypothesis are most appropriate for submission.
Human Investigations
JCO reviews reports on human experimentation in accordance with the precepts of the Helsinki Declaration. All reports must include:
- A statement that the investigators performed the human investigations after approval by a local Human Investigations Committee and in accord with an assurance filed with and approved by the Department of Health and Human Services, where appropriate.
- A statement that the investigators obtained informed consent from each participant or each participant’s guardian.
Originality
Manuscripts must contain original material. The only exception allows authors to submit and present abstracts (which might include oral presentations, presentations in books, posters, slides and other media types related to the abstract) of their research in open, scientific meetings.
The title page and cover letter should include a statement about the originality of the work, and disclose any previous abstracts, presentations, reports, or publications that contain any material that appears in the article. If a similar or supplemental publication exists, the authors should upload a copy as a supplemental file as part of the submission process. If applicable, authors should cite any previously published or closely related work within the text.
JCO will not accept for review any manuscript that is currently under review at another journal.
Authors can post their results in clinical trial registries without it being considered previously published or overlapping publication.
JCO follows the guidelines from the International Committee of Medical Journal Editors section on Overlapping Publications
(Overlapping Publications)
Proprietary Drug Names
Proprietary drug names are typically given once, at the first mention of the generic drug name in the text, and must accompany the generic drug name. The use of proprietary drug names or devices requires inclusion of the manufacturer’s name and location. JCO does not publish proprietary names in article titles or abstracts, and will modify the title and abstract of accepted manuscripts to contain the generic name only.
Protocol for All Phase III Studies
JCO believes that for the editors and reviewers to properly peer review a submission, a redaction of the protocol for all phase III studies must be provided. The protocol information must include the eligibility criteria, schema and dose modifications, and statistical section (including endpoints). Authors should upload this material as a Supplemental File. It will only be available to the editors and reviewers during the peer review process.
Recombinant DNA
All manuscripts dealing with recombinant DNA research must include a description of the physical and biologic containment procedures practiced, in accord with the National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules.
|
